RL
Relay Therapeutics, Inc.
RLAY · NASDAQ
$18.84 -0.69% (-$0.13)
1M -8.59%
Market Cap $4.13B
P/E Ratio -
Div. Yield -
ROE 42.27%
Piotroski F-Score Weak
3/9Valuation
21 /100
Expensive P/B 4.64x
P/S 398.90x
PEG N/A
Growth
78 /100
Growing Book val. growth 15.81%
Rev. growth 123.20%
FCF growth N/A
Profitability
0 /100
Weak FCF margin 2,050.29%
Op. margin 2,999.38%
Gross margin 566.59%
Quality
0 /100
Poor Asset turnover 0.01x
ROA 29.57%
ROIC 33.72%
Debt
100 /100
Low Current ratio 18.27x
Debt/Equity 0.03x
Net debt/EBITDA N/A
Stability
31 /100
Unstable Profitable years 0
EPS volatility 19.85%
Beta 1.70x
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o RLAY
Online
O podjetju
Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery.
V vašem jeziku še ni na voljo, zato je besedilo v angleščini.
Sector
Healthcare
Industry
Biotechnology
CEO
Sanjiv K. Patel
Employees
202
Headquarters
Cambridge
Prihajajoči dogodki
05 NOV.
Earnings
Upcoming earnings report